NASDAQ:ACHL Achilles Therapeutics (ACHL) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ACHL Stock Alerts $0.77 -0.01 (-1.27%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.74▼$0.8050-Day Range$0.78▼$1.5752-Week Range$0.74▼$1.76Volume260,086 shsAverage Volume664,695 shsMarket Capitalization$30.88 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Achilles Therapeutics alerts: Email Address Achilles Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside433.3% Upside$4.00 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.34) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.08 out of 5 starsMedical Sector717th out of 907 stocksBiological Products, Except Diagnostic Industry121st out of 153 stocks 3.0 Analyst's Opinion Consensus RatingAchilles Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAchilles Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of Achilles Therapeutics has been sold short.Short Interest Ratio / Days to CoverAchilles Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Achilles Therapeutics has recently decreased by 49.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAchilles Therapeutics does not currently pay a dividend.Dividend GrowthAchilles Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACHL. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Achilles Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows3 people have added Achilles Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achilles Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.38% of the stock of Achilles Therapeutics is held by insiders.Percentage Held by Institutions56.38% of the stock of Achilles Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Achilles Therapeutics are expected to grow in the coming year, from ($1.34) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achilles Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achilles Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchilles Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Achilles Therapeutics Stock (NASDAQ:ACHL)Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Read More ACHL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACHL Stock News HeadlinesApril 21, 2024 | americanbankingnews.comComparing Achilles Therapeutics (NASDAQ:ACHL) & Entera Bio (NASDAQ:ENTX)April 17, 2024 | msn.comAchilles Therapeutics plc - Depositary Receipt () (ACHL) Price Target Decreased by 56.41% to 2.89April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 16, 2024 | americanbankingnews.comAchilles Therapeutics plc (NASDAQ:ACHL) Sees Large Growth in Short InterestApril 5, 2024 | msn.comPiper downgrades Achilles to neutral, cites latest dataApril 4, 2024 | markets.businessinsider.comACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023April 4, 2024 | finanznachrichten.deAchilles Therapeutics PLC: Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsApril 4, 2024 | globenewswire.comAchilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 4, 2024 | globenewswire.comAchilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host ConditioningMarch 7, 2024 | finance.yahoo.comWill Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?February 22, 2024 | wsj.comAchilles Therapeutics PLC ADRFebruary 22, 2024 | benzinga.comAchilles Therapeutics Stock (NASDAQ:ACHL), Short Interest ReportFebruary 9, 2024 | investing.comAchilles Therapeutics PLC ADR (ACHL)February 5, 2024 | finance.yahoo.comAchilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 ConferenceDecember 22, 2023 | benzinga.comAchilles Therapeutics Stock (NASDAQ:ACHL) Dividends: History, Yield and DatesDecember 20, 2023 | seekingalpha.comACHL Achilles Therapeutics plcDecember 18, 2023 | finance.yahoo.comAchilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity PredictionNovember 22, 2023 | foxnews.comSteelers lose Kwon Alexander for season with torn Achilles: reportsNovember 14, 2023 | msn.comAchilles Therapeutics GAAP EPS of -$0.42 misses by $0.02October 29, 2023 | foxnews.comAs Aaron Rodgers rehabs from torn Achilles, doctor offers insight into recoverySeptember 23, 2023 | finanznachrichten.deAchilles Therapeutics PLC: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementSeptember 22, 2023 | uk.style.yahoo.comAre Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?September 21, 2023 | usatoday.comAaron Rodgers says he's starting 'road to recovery' after Achilles surgery went 'great'September 17, 2023 | usatoday.comJets QB Aaron Rodgers to miss rest of NFL season with torn AchillesSeptember 14, 2023 | cbsnews.comAaron Rodgers' Achilles injury is "not good," Jets head coach says, as star quarterback is set to get MRISeptember 14, 2023 | dailymail.co.ukAaron Rodgers said he was 'manifesting' a Super Bowl run for the Jets in interview with John McEnroe that aired just MINUTES before he suffered season-ending Achilles injurySee More Headlines Receive ACHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/04/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ACHL CUSIPN/A CIK1830749 Webwww.achillestx.com Phone44-0-20-8154-4600FaxN/AEmployees204Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+422.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.55% Return on Assets-37.54% Debt Debt-to-Equity RatioN/A Current Ratio8.57 Quick Ratio8.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.22Miscellaneous Outstanding Shares39,880,000Free Float37,734,000Market Cap$30.54 million OptionableNot Optionable Beta1.09 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Iraj Ali Ph.D. (Age 49)CEO & Director Comp: $1.7MDr. Karl Stuart Peggs M.D. (Age 57)Founder & Chief Medical Officer Dr. Sergio A. Quezada Ph.D. (Age 49)Founder & Chief Scientific Officer Mr. Robert Coutts (Age 40)Chief Financial Officer Dr. Mark William Lowdell BSc (Age 61)FRCPath, MICR, MSc, Ph.D., Founder Dr. Charles Swanton FMEDSCI (Age 51)M.D., Ph.D., Founder Mr. Lee M. SternVice President of Investor Relations & External CommunicationsMr. Daniel Carey Cazel HoodGeneral Counsel & Company SecretaryJulia WilsonHead of CommunicationsMr. Tariq AhmedExecutive Vice President of PeopleMore ExecutivesKey CompetitorsCortexymeNASDAQ:CRTXMiNK TherapeuticsNASDAQ:INKTIN8bioNASDAQ:INABSurrozenNASDAQ:SRZNWindtree TherapeuticsNASDAQ:WINTView All CompetitorsInstitutional OwnershipFcpm Iii Services B.V.Bought 2,390,050 shares on 3/7/2024Ownership: 5.861%Vestal Point Capital LPBought 108,083 shares on 2/14/2024Ownership: 0.265%View All Institutional Transactions ACHL Stock Analysis - Frequently Asked Questions Should I buy or sell Achilles Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACHL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACHL, but not buy additional shares or sell existing shares. View ACHL analyst ratings or view top-rated stocks. What is Achilles Therapeutics' stock price target for 2024? 3 analysts have issued twelve-month price objectives for Achilles Therapeutics' shares. Their ACHL share price targets range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 433.3% from the stock's current price. View analysts price targets for ACHL or view top-rated stocks among Wall Street analysts. How have ACHL shares performed in 2024? Achilles Therapeutics' stock was trading at $0.8890 on January 1st, 2024. Since then, ACHL shares have decreased by 15.6% and is now trading at $0.75. View the best growth stocks for 2024 here. Are investors shorting Achilles Therapeutics? Achilles Therapeutics saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 37,800 shares, a decrease of 49.5% from the March 31st total of 74,800 shares. Based on an average daily volume of 770,200 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the company are short sold. View Achilles Therapeutics' Short Interest. When is Achilles Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ACHL earnings forecast. How were Achilles Therapeutics' earnings last quarter? Achilles Therapeutics plc (NASDAQ:ACHL) announced its quarterly earnings data on Thursday, April, 4th. The company reported ($0.46) earnings per share for the quarter. When did Achilles Therapeutics IPO? Achilles Therapeutics (ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO. How do I buy shares of Achilles Therapeutics? Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACHL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
